Leica Biosystems and Bristol Myers Squibb Announce Strategic Partnership to Drive Innovation in Companion Diagnostics and Enable Precision Medicine
Newcastle upon Tyne, United Kingdom, May 22, 2025 -Leica Biosystems, a global leader in anatomic pathology solutions, and Bristol Myers Squibb, a leading global biopharmaceutical company, have announced a strategic partnership to co-develop and commercialize companion diagnostic (CDx) tests that support targeted cancer therapies. This partnership expands a long-standing relationship and reflects both organizations’ shared commitment to advancing precision medicine and improving patient outcomes.
The partnership will combine Leica Biosystems’ proven expertise in automated, tissue-based diagnostics with Bristol Myers Squibb’s innovative therapeutic portfolio. Together, the companies aim to accelerate the development of high-quality CDx solutions that enable the selection of patients most likely to benefit from specific oncology therapies.
As oncology moves toward increasingly personalized treatment approaches, the demand for robust diagnostic tools that can precisely identify eligible patients has never been greater. Companion diagnostics play a critical role in guiding clinical decision-making, improving outcomes, and reducing healthcare costs. Today’s CDx solutions must not only deliver diagnostic precision but also integrate seamlessly into lab workflows, a complex challenge that Leica Biosystems is uniquely positioned to meet with its comprehensive portfolio of staining, imaging, and AI-powered image analysis solutions.
This collaboration with Bristol Myers Squibb is designed to streamline CDx development from early-stage assay transfer through commercialization, accelerating access to personalized cancer treatments and supporting labs with scalable, regulatory-compliant solutions.
"This expanded partnership with Bristol Myers Squibb reinforces our mission to transform cancer diagnostics,” said Karan Arora, Senior Vice President of Advanced Assays, AI, and Pharma Services at Leica Biosystems. “We are committed to supporting the transition from discovery to delivery, helping our partners bring precision diagnostics into routine care. Our investments in AI-enabled pathology and our ability to onboard early-phase assays position us to lead the future of companion diagnostics."
Leica Biosystems’ CDx development program—currently based out of Centers for Enabling Precision Medicine in the United Kingdom, the United States, and China—partners with pharma companies globally to drive earlier, more accurate cancer diagnoses and help unlock patient access to novel cancer therapies.
To learn more about Leica Biosystems and Bristol Myers Squibb, please visit their official websites.
Leica Biosystems
Bristol Myers Squibb
About Leica Biosystems
Leica Biosystems is a cancer diagnostics company and a global leader in workflow solutions. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As the only company to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step. The company’s mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of its corporate culture.
